Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non-cash Items (2020 - 2023)

Barinthus Biotherapeutics' Non-cash Items history spans 4 years, with the latest figure at $4.1 million for Q3 2023.

  • For Q3 2023, Non-cash Items fell 52.87% year-over-year to $4.1 million; the TTM value through Sep 2023 reached $4.1 million, down 52.87%, while the annual FY2022 figure was $1.5 million, 91.29% down from the prior year.
  • Non-cash Items reached $4.1 million in Q3 2023 per BRNS's latest filing, down from $6.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $19.8 million in Q2 2021 to a low of $1.5 million in Q4 2022.
  • Average Non-cash Items over 4 years is $9.8 million, with a median of $8.8 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: skyrocketed 448.79% in 2021, then tumbled 91.29% in 2022.
  • A 4-year view of Non-cash Items shows it stood at $3.1 million in 2020, then surged by 448.79% to $17.0 million in 2021, then crashed by 91.29% to $1.5 million in 2022, then skyrocketed by 177.61% to $4.1 million in 2023.
  • Per Business Quant, the three most recent readings for BRNS's Non-cash Items are $4.1 million (Q3 2023), $6.5 million (Q2 2023), and $9.0 million (Q1 2023).